Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. Issue 8 (3rd July 2019)

• Record Type: Journal Article
• Authors: Al-Mansour, Zeina; Li, Hongli; Cook, James R.; Constine, Louis S.; Couban, Stephen; Stewart, Douglas A.; Shea, Thomas C.; Porcu, Pierluigi; Winter, Jane N.; Kahl, Brad S.; Smith, Sonali M.; Marcellus, Deborah C.; Barton, Kevin P.; Mills, Glenn M.; LeBlanc, Michael; Rimsza, Lisa M.; Forman, Stephen J.; Leonard, John P.; Fisher, Richard I.; Friedberg, Jonathan W.; Stiff, Patrick J.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 8(2019)
• Page Start: 1934
• Page End: 1941
• Publication Date: 2019-07-03
• Subjects: T-NHL treatment -- consolidative autotransplant -- high-risk T-NHL; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1563691
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility ( n = 1), choice ( n = 2), or progression ( n = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% ( p = .56), and 40% vs. 45% ( p = .98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.